Literature DB >> 19110721

Identification of genes that exhibit changes in expression on the 8p chromosomal arm by the Systematic Multiplex RT-PCR (SM RT-PCR) and DNA microarray hybridization methods.

Fumiichiro Yamamoto1, Miyako Yamamoto.   

Abstract

Losses of the p-arm of chromosome 8 are frequently observed in breast, prostate, and other types of cancers. Using the Systematic Multiplex RT-PCR (SM RT-PCR) method and the DNA microarray hybridization method, we examined the expression of 273 genes located on the p-arm of chromosome 8 in five breast and three prostate human cancer cell lines. We observed frequent decreases in expression of two dozen genes and increases in expression of several genes on this chromosomal arm. These changes in gene expression of the cell lines were later confirmed by real-time qRT-PCR. Additionally and more importantly, we found that a number of these variations were also observed in the majority of clinical cases of breast cancer we examined. These included downregulation of the MYOM2, NP_859074, NP_001034551, NRG1, PHYIP (PHYHIP), Q7Z2R7, SFRP1, and SOX7 genes, and upregulation of the ESCO2, NP_115712 (GINS4), Q6P464, and TOPK (PBK) genes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110721      PMCID: PMC6042003          DOI: 10.3727/105221608786883816

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  40 in total

1.  Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene.

Authors:  D G Albertson; B Ylstra; R Segraves; C Collins; S H Dairkee; D Kowbel; W L Kuo; J W Gray; D Pinkel
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

2.  Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action.

Authors:  P W Finch; X He; M J Kelley; A Uren; R P Schaudies; N C Popescu; S Rudikoff; S A Aaronson; H E Varmus; J S Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

3.  Quantitative monitoring of gene expression patterns with a complementary DNA microarray.

Authors:  M Schena; D Shalon; R W Davis; P O Brown
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

4.  Comparative genomics on FGF20 orthologs.

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Oncol Rep       Date:  2005-07       Impact factor: 3.906

5.  Functional epigenomics identifies genes frequently silenced in prostate cancer.

Authors:  Dimitri Lodygin; Alexey Epanchintsev; Antje Menssen; Joachim Diebold; Heiko Hermeking
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

6.  Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease.

Authors:  J Koch; S Gärtner; C M Li; L E Quintern; K Bernardo; O Levran; D Schnabel; R J Desnick; E H Schuchman; K Sandhoff
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

7.  Gene expression analysis of an integrin family of genes by systematic multiplex reverse transcription-polymerase chain reaction.

Authors:  Miyako Yamamoto; Ami Yamamoto; Patricia C Leung; Fumiichiro Yamamoto
Journal:  Electrophoresis       Date:  2004-07       Impact factor: 3.535

8.  Transposition and amplification of oncogene-related sequences in human neuroblastomas.

Authors:  N E Kohl; N Kanda; R R Schreck; G Bruns; S A Latt; F Gilbert; F W Alt
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

Review 9.  Chromosomal deletions and tumor suppressor genes in prostate cancer.

Authors:  J T Dong
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

10.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays.

Authors:  D Pinkel; R Segraves; D Sudar; S Clark; I Poole; D Kowbel; C Collins; W L Kuo; C Chen; Y Zhai; S H Dairkee; B M Ljung; J W Gray; D G Albertson
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

View more
  6 in total

1.  Allelotyping identification of genomic alterations in rectal chromosomally unstable tumors without preoperative treatment.

Authors:  Benoît Romain; Agnès Neuville; Nicolas Meyer; Cécile Brigand; Serge Rohr; Anne Schneider; Marie-Pierre Gaub; Dominique Guenot
Journal:  BMC Cancer       Date:  2010-10-18       Impact factor: 4.430

2.  Rare and frequent promoter methylation, respectively, of TSHZ2 and 3 genes that are both downregulated in expression in breast and prostate cancers.

Authors:  Miyako Yamamoto; Emili Cid; Samuel Bru; Fumiichiro Yamamoto
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

3.  Reduced Zeb1 Expression in Prostate Cancer Cells Leads to an Aggressive Partial-EMT Phenotype Associated with Altered Global Methylation Patterns.

Authors:  Jenna Kitz; Cory Lefebvre; Joselia Carlos; Lori E Lowes; Alison L Allan
Journal:  Int J Mol Sci       Date:  2021-11-27       Impact factor: 5.923

4.  Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.

Authors:  Yu Xiao; Lingao Ju; Kaiyu Qian; Wan Jin; Gang Wang; Yan Zhao; Wei Jiang; Nan Liu; Kai Wu; Minsheng Peng; Rui Cao; Sheng Li; Hongjie Shi; Yan Gong; Hang Zheng; Tongzu Liu; Yongwen Luo; Haoli Ma; Luyuan Chang; Gang Li; Xinyue Cao; Ye Tian; Zilin Xu; Zhonghua Yang; Liuying Shan; Zhongqiang Guo; Dongai Yao; Xianlong Zhou; Xintong Chen; Zicheng Guo; Dongmei Liu; Song Xu; Chundong Ji; Fang Yu; Xin Hong; Jun Luo; Hong Cao; Yi Zhang; Xinghuan Wang
Journal:  Clin Transl Med       Date:  2022-08

Review 5.  Role of motor proteins in human cancers.

Authors:  Iman Hassan Ibrahim; Amany Balah; Abrar Gomaa Abd Elfattah Hassan; Heba Gamal Abd El-Aziz
Journal:  Saudi J Biol Sci       Date:  2022-09-06       Impact factor: 4.052

6.  Establishment of cohesion 1 homolog 2 facilitates cell aggressive behaviors and induces poor prognosis in renal cell carcinoma.

Authors:  Qiu-Li Wang; Ling Liu
Journal:  J Clin Lab Anal       Date:  2020-01-15       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.